BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Gilead Sciences, Inc. (GILD)'s Viread Reduces HIV Risk for Drug Users in Study


6/13/2013 7:36:08 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Gilead Sciences Inc. (GILD)’s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV’s spread. In a trial involving 2,413 HIV-negative drug users in Bangkok over five years, those who received Viread daily were 49 percent less likely to get infected with HIV than those who got a placebo, researchers from the Thai Ministry of Public Health and the U.S. Centers for Disease Control and Prevention reported today in the Lancet. The findings confirm the results of earlier studies that show Foster City, California-based Gilead’s Viread and Truvada can prevent infections among people at risk of catching the virus, an approach called pre-exposure prophylaxis, or PrEP. Health officials are planning pilot programs to turn the promising study into a real-world public health intervention.

Help employers find you! Check out all the jobs and post your resume.


Read at Bloomberg
Read at Fox News
Read at CTV.ca
Read at CBS News
Read at New York Times

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES